Theravance Biopharma Inc (TBPH) Given Average Rating of “Hold” by Analysts

Shares of Theravance Biopharma Inc (NASDAQ:TBPH) have earned a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $41.33.

TBPH has been the subject of several analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research note on Tuesday, November 7th. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Robert W. Baird restated a “sell” rating and issued a $22.00 target price on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Finally, Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th.

Theravance Biopharma (TBPH) opened at $27.42 on Thursday. Theravance Biopharma has a 12 month low of $23.15 and a 12 month high of $43.44. The company has a debt-to-equity ratio of 1.21, a current ratio of 7.53 and a quick ratio of 7.21.

Several large investors have recently added to or reduced their stakes in TBPH. BlackRock Inc. raised its holdings in shares of Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after acquiring an additional 126,393 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after buying an additional 116,981 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Theravance Biopharma by 174.8% during the 2nd quarter. Wells Fargo & Company MN now owns 88,688 shares of the biopharmaceutical company’s stock valued at $3,533,000 after buying an additional 56,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Theravance Biopharma during the 2nd quarter valued at about $1,235,000. Finally, Northern Trust Corp raised its holdings in shares of Theravance Biopharma by 6.1% during the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after buying an additional 30,611 shares in the last quarter. 86.02% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Theravance Biopharma Inc (TBPH) Given Average Rating of “Hold” by Analysts” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/21/theravance-biopharma-inc-tbph-given-average-rating-of-hold-by-analysts.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit